Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Harvard Business School
Colorcon
Cantor Fitzgerald
Farmers Insurance

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 10,213,444

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,213,444
Title:Composition and method for treating bipolar disorder
Abstract: Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combination therapy of minocycline and acetylsalicylic acid delivered in doses that improve metabolic function and/or exert immune-modulating and/or anti-inflammatory effects. Also disclosed is a method for treating individuals suffering from the indicated disorders.
Inventor(s): Drevets; Wayne Curtis (Newton, PA), Yates; William Robert (Tulsa, OK), Savitz; Jonathan Bradley (Tulsa, OK), Preskorn; Sheldon H. (Wichita, KS)
Assignee: Laureate Institute For Brain Research (Tulsa, OK)
Application Number:15/532,851
Patent Claims:see list of patent claims

Details for Patent 10,213,444

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Novartis Pharms ILARIS canakinumab INJECTABLE; SUBCUTANEOUS 125319 001 2009-06-17 ➤ Sign Up Laureate Institute For Brain Research (Tulsa, OK) ➤ Sign Up RX search
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27 ➤ Sign Up Laureate Institute For Brain Research (Tulsa, OK) ➤ Sign Up RX Orphan search
Ucb Inc CIMZIA certolizumab pegol INJECTABLE; INJECTION 125160 001 2008-04-22 ➤ Sign Up Laureate Institute For Brain Research (Tulsa, OK) ➤ Sign Up RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up Laureate Institute For Brain Research (Tulsa, OK) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
Chinese Patent Office
Moodys
Accenture
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.